Literature DB >> 31504634

Evidence That Blunted CD4 T-Cell Responses Underlie Deficient Protective Antibody Responses to Influenza Vaccines in Repeatedly Vaccinated Human Subjects.

Katherine A Richards1, Ian Shannon2, John J Treanor3, Hongmei Yang4, Jennifer L Nayak2, Andrea J Sant1.   

Abstract

Despite the benefits of yearly influenza vaccination, accumulating evidence suggests that diminished vaccine efficacy may be related to repeated vaccination. Although studied at the level of B-cell responses, CD4 T-cell responses have not yet been examined. In this study, we analyze CD4 T-cell responses to influenza vaccination in subjects who differ in their vaccine history. We find a striking disparity in their responses, with previously vaccinated subjects exhibiting significantly blunted CD4 T-cell responses and diminished antibody responses. These results suggest that limiting CD4 T-cell help mteaserrlie the diminished or altered antibody responses in repeatedly vaccinated subjects.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CD4 T cells; cell-mediated immunity; influenza vaccine; influenza virus

Mesh:

Substances:

Year:  2020        PMID: 31504634      PMCID: PMC8494023          DOI: 10.1093/infdis/jiz433

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  15 in total

Review 1.  Influenza vaccine failure: failure to protect or failure to understand?

Authors:  Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2018-06-26       Impact factor: 5.217

Review 2.  Tfh cell response in influenza vaccines in humans: what is visible and what is invisible.

Authors:  Hideki Ueno
Journal:  Curr Opin Immunol       Date:  2019-03-25       Impact factor: 7.486

Review 3.  With a Little Help from T Follicular Helper Friends: Humoral Immunity to Influenza Vaccination.

Authors:  Marios Koutsakos; Thi H O Nguyen; Katherine Kedzierska
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

Review 4.  Effector mechanisms of influenza-specific antibodies: neutralization and beyond.

Authors:  Federica Sicca; Sam Neppelenbroek; Anke Huckriede
Journal:  Expert Rev Vaccines       Date:  2018-09-03       Impact factor: 5.217

5.  Likelihood ratio and score tests to test the non-inferiority (or equivalence) of the odds ratio in a crossover study with binary outcomes.

Authors:  Xiaochun Li; Huilin Li; Man Jin; Judith D Goldberg
Journal:  Stat Med       Date:  2016-04-19       Impact factor: 2.373

Review 6.  Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?

Authors:  Karlynn E Neu; Carole J Henry Dunand; Patrick C Wilson
Journal:  Curr Opin Immunol       Date:  2016-06-03       Impact factor: 7.486

7.  CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine.

Authors:  Jennifer L Nayak; Theresa F Fitzgerald; Katherine A Richards; Hongmei Yang; John J Treanor; Andrea J Sant
Journal:  J Infect Dis       Date:  2012-11-12       Impact factor: 5.226

8.  Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses.

Authors:  Jennifer L Nayak; Katherine A Richards; Hongmei Yang; John J Treanor; Andrea J Sant
Journal:  J Infect Dis       Date:  2014-11-06       Impact factor: 5.226

9.  Multi-epitope Models Explain How Pre-existing Antibodies Affect the Generation of Broadly Protective Responses to Influenza.

Authors:  Veronika I Zarnitsyna; Jennie Lavine; Ali Ellebedy; Rafi Ahmed; Rustom Antia
Journal:  PLoS Pathog       Date:  2016-06-23       Impact factor: 6.823

10.  Immunizing the Immune: Can We Overcome Influenza's Most Formidable Challenge?

Authors:  Ali H Ellebedy
Journal:  Vaccines (Basel)       Date:  2018-09-22
View more
  8 in total

Review 1.  Aging and Options to Halt Declining Immunity to Virus Infections.

Authors:  Miguel Ángel Palacios-Pedrero; Albert D M E Osterhaus; Tanja Becker; Husni Elbahesh; Guus F Rimmelzwaan; Giulietta Saletti
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

2.  Balanced Cellular and Humoral Immune Responses Targeting Multiple Antigens in Adults Receiving a Quadrivalent Inactivated Influenza Vaccine.

Authors:  Esther Dawen Yu; Alba Grifoni; Aaron Sutherland; Hannah Voic; Eric Wang; April Frazier; Natalia Jimenez-Truque; Sandra Yoder; Sabrina Welsh; Stacey Wooden; Wayne Koff; Buddy Creech; Alessandro Sette; Ricardo da Silva Antunes
Journal:  Vaccines (Basel)       Date:  2021-04-23

3.  Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults.

Authors:  Athena P Y Li; Carolyn A Cohen; Nancy H L Leung; Vicky J Fang; Shivaprakash Gangappa; Suryaprakash Sambhara; Min Z Levine; A Danielle Iuliano; Ranawaka A P M Perera; Dennis K M Ip; J S Malik Peiris; Mark G Thompson; Benjamin J Cowling; Sophie A Valkenburg
Journal:  NPJ Vaccines       Date:  2021-02-16       Impact factor: 9.399

Review 4.  Potentiating Lung Mucosal Immunity Through Intranasal Vaccination.

Authors:  Sean A Nelson; Andrea J Sant
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

5.  Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination.

Authors:  Katharina Wild; Maike Smits; Saskia Killmer; Shirin Strohmeier; Christoph Neumann-Haefelin; Bertram Bengsch; Florian Krammer; Martin Schwemmle; Maike Hofmann; Robert Thimme; Katharina Zoldan; Tobias Boettler
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

6.  Strong influenza-induced TFH generation requires CD4 effectors to recognize antigen locally and receive signals from continuing infection.

Authors:  Priyadharshini Devarajan; Allen M Vong; Catherine H Castonguay; Olivia Kugler-Umana; Bianca L Bautista; Michael C Jones; Karen A Kelly; Jingya Xia; Susan L Swain
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-22       Impact factor: 12.779

7.  Intranasal Nanoparticle Vaccination Elicits a Persistent, Polyfunctional CD4 T Cell Response in the Murine Lung Specific for a Highly Conserved Influenza Virus Antigen That Is Sufficient To Mediate Protection from Influenza Virus Challenge.

Authors:  Sean A Nelson; Thamotharampillai Dileepan; Amy Rasley; Marc K Jenkins; Nicholas O Fischer; Andrea J Sant
Journal:  J Virol       Date:  2021-07-26       Impact factor: 5.103

8.  Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans.

Authors:  K A Richards; S Moritzky; I Shannon; T Fitzgerald; H Yang; A Branche; D J Topham; J J Treanor; J Nayak; Andrea J Sant
Journal:  NPJ Vaccines       Date:  2020-08-26       Impact factor: 7.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.